Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 5/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608427 | 0.84 | VNN1 (0.42) | SSTR4TACR3DPP4VNN1 | |
| SCHEMBL13254923 | 0.83 | SSTR4 (0.42) | SSTR4TACR3DPP4HDAC3HDAC1 | |
| SCHEMBL2712662 | 0.79 | SSTR4 (0.53) | SSTR4TACR3DPP4HDAC3HDAC1 | |
| SCHEMBL1905128 | 0.79 | AKT1 (0.40) | CTSLCTSBCTSSPDE2A | |
| SCHEMBL361827 | 0.78 | MAPK1 (0.39) | SSTR4TACR3PDE2AHDAC3HDAC1 | |
| SCHEMBL2173859 | 0.78 | ALDH1A1 (0.41) | SSTR4TACR3PDE2AHDAC3HDAC1 | |
| SCHEMBL16161986 | 0.78 | HDAC4 (0.47) | SSTR4TACR3HDAC3HDAC1HDAC2 | |
| SCHEMBL9900730 | 0.77 | VNN1 (0.40) | TACR3HDAC6VNN1 | |
| SCHEMBL3560390 | 0.75 | SSTR4 (0.56) | SSTR4TACR3HDAC3HDAC1HDAC2 | |
| SCHEMBL27224162 | 0.75 | ALDH1A1 (0.40) | SSTR4TACR3PDE2AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | CTSL 2188/4885CTSB 949/4885CTSS 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.